← Leaderboards
Michael A. Curran
University Of Tx Md Anderson Can Ctr
$2,810,605
Attributed
$2,810,605
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $927.2K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,810,605 · 2
By mechanism
R01$2,365,105 · 1
R21$445,500 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Albert Koong$7,304,561
- Boyi Gan$13,125,533
- Christopher Chad Quarles$12,985,497
- Michael W Andreeff$17,991,896
- Florencia McAllister$3,653,632
Others in their field
Other Emerging Leaders on “Myelogenous”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Frederic Geissmann · Sloan-Kettering Inst Can Research$10,272,929
- Michael Jay Corley · University Of Hawaii At Manoa$6,909,053
- Dionna Whitney Williams · Johns Hopkins University$5,825,076
- William Karl Decker · Baylor College Of Medicine$5,278,786
- Daniel Lucas · Cincinnati Childrens Hosp Med Ctr$4,302,957
Research focus
MyelogenousMouse ModelResponseTumorIn VitroMalignant NeoplasmsMediatingMyeloid CellsTumor ImmunityCellsGlycolysisEquilibriumFibroblastsBloodFailureFitnessHypoxiaCoupledAutomobile DrivingConsumptionAngiogenesis InhibitorsCellular Metabolic ProcessAnimalsCtla4 Gene
Grant awards (6)
Breaking down tumor immune privilege through targeted hypoxia reduction$457,607
R01 · FY2024 · CA · contact PI
Breaking down tumor immune privilege through targeted hypoxia reduction$472,058
R01 · FY2023 · CA · contact PI
Breaking down tumor immune privilege through targeted hypoxia reduction$472,058
R01 · FY2022 · CA · contact PI
Breaking down tumor immune privilege through targeted hypoxia reduction$481,691
R01 · FY2021 · CA · contact PI
Breaking down tumor immune privilege through targeted hypoxia reduction$481,691
R01 · FY2020 · CA · contact PI
Reversal of neurodegeneration through pTau clearance by chimeric scavenger receptor monocytes$445,500
R21 · FY2020 · AG · contact PI